Inflammatory state does not affect the antiplatelet efficacy of potent P2Y12 inhibitors in ACS

Area of Science:

• Cardiology
• Immunology
• Pharmacology

Background:

• Inflammation is a key driver of atherosclerosis and acute coronary syndromes (ACS).
• Understanding inflammatory markers' impact on antiplatelet therapy is crucial for ACS management.
• Potent P2Y12 inhibitors are standard treatment for ACS, but their efficacy in inflammatory states requires clarification.

Purpose of the Study:

• To assess the association between inflammatory markers (hsCRP, hsIL-6, sCD40L) and platelet reactivity in ACS patients on ticagrelor and prasugrel.
• To investigate correlations between these markers and standard inflammatory indicators (WBC, fibrinogen).
• To examine differences in inflammatory marker concentrations based on diabetes status and statin pre-treatment.

Main Methods:

• Prospective, observational study of 338 ACS patients treated with ticagrelor or prasugrel.
• Measurement of high-sensitivity C-reactive protein (hsCRP), high-sensitivity interleukin-6 (hsIL-6), and soluble CD40 ligand (sCD40L) using turbidimetric and ELISA assays.
• Assessment of platelet reactivity via multiple electrode aggregometry and correlation analysis with inflammatory markers and clinical factors.

Main Results:

• A weak inverse correlation was observed between hsIL-6 and platelet reactivity (r ≤ -0.125).
• hsIL-6 and hsCRP positively correlated with white blood cell (WBC) and fibrinogen levels (r ≥ 0.199).
• Insulin-dependent diabetes mellitus was linked to higher hsIL-6, while statin pre-treatment correlated with lower hsIL-6.

Conclusions:

• Inflammatory status does not significantly affect the antiplatelet efficacy of potent P2Y12 inhibitors during the acute phase of ACS.
• These findings support the safety and efficacy of ticagrelor and prasugrel in ACS patients with a high inflammatory burden.
• The study highlights the continued effectiveness of potent P2Y12 inhibitors despite varying inflammatory profiles.